Citalopram for Cocaine Dependence
Information source: The University of Texas Health Science Center, Houston
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine Dependence
Intervention: Citalopram (Drug); Citalopram (Drug); Placebo (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Joy Schmitz Official(s) and/or principal investigator(s): Joy M Schmitz, Ph.D., Principal Investigator, Affiliation: University of Texas at Houston
Overall contact: Jessica Vincent, BS, Phone: 7135003784, Email: Jessica.Vincent@uth.tmc.edu
Summary
This is a phase 2 clinical trial of citalopram pharmacotherapy for treatment of cocaine
dependence. Using a double-blind, randomized controlled design, eligible cocaine dependent
patients will be assigned equally to one of three medication conditions: placebo or the
Selective serotonin re-uptake inhibitor (SSRI) agent, citalopram at either 20 mg per day or
40 mg per day. It is hypothesized that citalopram will reduce cocaine use and increase
periods of sustained abstinence substantially more than placebo. Performance on a set of
behavioral tasks of impulsivity will be analyzed as potential predictors of treatment
response.
Clinical Details
Official title: Clinical Trial of Serotonin Medication Combination in Cocaine Dependence
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Abstinence
Secondary outcome: Cocaine Use DaysCocaine-negative Urines Retention in Treatment
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- between 18 and 60 years of age
- meet DSM-IV criteria for current cocaine dependence
- be in acceptable health on the basis of interview, medical history and physical exam
- able to provide the names of at least 2 persons who can generally locate their
whereabouts.
Exclusion Criteria:
- diagnosis of any psychoactive substance dependence other than cocaine, marijuana, or
nicotine
- have a psychiatric disorder or neurological disease or disorder requiring ongoing
treatment and/or making study participation unsafe
- medical conditions contraindicating citalopram pharmacotherapy
- taking medications known to have significant drug interactions with the study
medication
- pregnant or nursing for female patients
- having plans to leave the immediate geographical area within 3 months
Locations and Contacts
Jessica Vincent, BS, Phone: 7135003784, Email: Jessica.Vincent@uth.tmc.edu
UT-Houston Behavioral and Biomedical Sciences Building, Houston, Texas 77054, United States; Recruiting Jessica Vincent, BS, Phone: 713-500-3784, Email: Jessica.Vincent@uth.tmc.edu Joy M Schmitz, Ph.D., Principal Investigator
Additional Information
Starting date: December 2010
Last updated: February 14, 2012
|